Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma

  • Technology appraisal guidance
  • TA178
  • Published: 

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final appraisal determination

After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on Bevacizumab, sorafenib, sunitinib and temsirolimus for renal cell carcinoma and submitted it to the Institute.

The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales.

Please note that the appeal period for this appraisal will close at 5pm on 12 May 2009.

This page was last updated: 30 March 2010